General Information of the Drug (ID: M6APDG04327)
Name
SD1003
Status
Preclinical
TTD Drug ID
DSM03D
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cathepsin B (CTSB)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Cathepsin B (CTSB) is a therapeutic target for SD1003. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of SD1003 through regulating the expression of Cathepsin B (CTSB). [1], [2]
References
Ref 1 A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018 Nov;28(11):1062-1076. doi: 10.1038/s41422-018-0097-4. Epub 2018 Oct 8.
Ref 2 Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. doi: 10.1038/s41573-019-0036-1. Epub 2019 Sep 2.